Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to -$17.4 million.

  • Kyntra Bio's Change in Accured Expenses fell 14907.88% to -$17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$124.8 million, marking a year-over-year decrease of 64997.6%. This contributed to the annual value of -$93.8 million for FY2024, which is 8841.66% down from last year.
  • As of Q3 2025, Kyntra Bio's Change in Accured Expenses stood at -$17.4 million, which was down 14907.88% from $1.0 million recorded in Q2 2025.
  • Kyntra Bio's 5-year Change in Accured Expenses high stood at $66.0 million for Q1 2022, and its period low was -$76.7 million during Q4 2024.
  • Its 5-year average for Change in Accured Expenses is -$4.5 million, with a median of $468000.0 in 2023.
  • Per our database at Business Quant, Kyntra Bio's Change in Accured Expenses soared by 2254659.86% in 2022 and then crashed by 1648418.8% in 2024.
  • Quarter analysis of 5 years shows Kyntra Bio's Change in Accured Expenses stood at -$15.6 million in 2021, then surged by 121.7% to $3.4 million in 2022, then plummeted by 86.19% to $468000.0 in 2023, then crashed by 16484.19% to -$76.7 million in 2024, then soared by 77.25% to -$17.4 million in 2025.
  • Its Change in Accured Expenses stands at -$17.4 million for Q3 2025, versus $1.0 million for Q2 2025 and -$31.7 million for Q1 2025.